CooperCompanies Reports Second Quarter Revenue Growth, Updates Full Fiscal Year Guidance

Published on May 30, 2025
SAN RAMON, Calif.—CooperCompanies (Nasdaq: COO), a medical device company, yesterday announced financial results for its fiscal second quarter ended April 30, 2025. In the quarter, CooperCompanies reported that revenue increased 6 percent year-over-year to $1,002.3 million. CooperVision (CVI) revenue was up 5 percent to $669.6 million, and CooperSurgical (CSI) revenue was up 8 percent to $332.7 million, according to the announcement.
Continue reading on website
Other news

Iolyx Therapeutics releases phase 2 results for ILYX-002 in autoimmune-associated dry eye disease

May 29, 2025
According to the company, results showed “a meaningful clinical improvement in ocular surface health” and significance for both staining end points at day 15.

Pangaea Data and Topcon Healthcare announce strategic investment

May 30, 2025
The partnership aims to accelerate Pangaea’s efforts to address critical care gaps in eye health and systemic disease.